Heidi Ammerlaan
- Infectious Diseases top 5%
- Molecular Medicine top 2%
- Epidemiology
- Clinical Biochemistry top 2%
- Applied Microbiology and Biotechnology top 1%
- Co-authors
- Marc J. M. BontenWouter C. RottierJan KluytmansHeiman WertheimJan NouwenPaul D. van der LindenJ W Dorigo-ZetsmaStéphan Harbarth
- Topics
- Bacterial Identification and Susceptibility Testing (9 papers)Antimicrobial Resistance in Staphylococcus (6 papers)Antibiotic Use and Resistance (5 papers)
- Journals
- Clinical Infectious DiseasesJournal of Antimicrobial ChemotherapyJournal of Advanced Nursing
- Partner nations
- NetherlandsUnited StatesUnited Kingdom
In The Last Decade
Heidi Ammerlaan
20 papers receiving 572 citations
Peers
Comparison fields: 5 of 72
- Infectious Diseases 271
- Molecular Medicine 215
- Epidemiology 214
- Clinical Biochemistry 178
- Applied Microbiology and Biotechnology 142
Countries citing papers authored by Heidi Ammerlaan
This map shows the geographic impact of Heidi Ammerlaan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heidi Ammerlaan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heidi Ammerlaan more than expected).
Fields of papers citing papers by Heidi Ammerlaan
This network shows the impact of papers produced by Heidi Ammerlaan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heidi Ammerlaan. The network helps show where Heidi Ammerlaan may publish in the future.
Co-authorship network of co-authors of Heidi Ammerlaan
This figure shows the co-authorship network connecting the top 25 collaborators of Heidi Ammerlaan. A scholar is included among the top collaborators of Heidi Ammerlaan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heidi Ammerlaan. Heidi Ammerlaan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 0 | |
| 3 | 0 | |
| 4 | 2 | |
| 5 | 3 | |
| 6 | 2 | |
| 7 | 3 | |
| 8 | 13 | |
| 9 | 12 | |
| 10 | 12 | |
| 11 | Case series on acute HCV in HIV-negative men in regular clinical practice: a call for action. | 2 |
| 12 | 7 | |
| 13 | 23 | |
| 14 | 40 | |
| 15 | 159 | |
| 16 | 15 | |
| 17 | 187 | |
| 18 | 72 | |
| 19 | [Optimisation of the antibiotic policy in the Netherlands. XII. The SWAB guideline for antimicrobial eradication of MRSA in carriers]. | 9 |
| 20 | 6 |
About Heidi Ammerlaan
Heidi Ammerlaan is a scholar working on Applied Microbiology and Biotechnology, Clinical Biochemistry and Molecular Medicine, having authored 23 papers that have together received 585 indexed citations. Recurring topics across this work include Bacterial Identification and Susceptibility Testing (9 papers), Antimicrobial Resistance in Staphylococcus (6 papers) and Antibiotic Use and Resistance (5 papers). The work is most often cited by research in Applied Microbiology and Biotechnology (142 citations), Molecular Medicine (215 citations) and Clinical Biochemistry (178 citations). Heidi Ammerlaan has collaborated with scholars based in Netherlands, United States and United Kingdom. Frequent co-authors include Marc J. M. Bonten, Wouter C. Rottier, Jan Kluytmans, Heiman Wertheim, Jan Nouwen, Paul D. van der Linden, J W Dorigo-Zetsma, Stéphan Harbarth, Massimo Antonelli and Antoni Torres. Their work appears in journals such as Clinical Infectious Diseases, Journal of Antimicrobial Chemotherapy and Journal of Advanced Nursing.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.